title: Impact of baseline echocardiography on treatment outcome in primary care patients with newly detected arterial hypertension: a randomized trial.
abstract: BACKGROUND
  The objective of this study was to test whether baseline echocardiography in newly detected hypertension improves left ventricular mass index and blood pressure control. This is a randomized trial with primary care patients.
  
  
  METHODS
  After routine clinical work-up 177 consecutive patients with newly detected hypertension were randomized according to result of their echocardiogram (echo group and control group). Treating physicians were encouraged to prescribe angiotensin II receptor antagonist therapy for patients with evidence of hypertensive target organ damage. Mean blood pressure (BP) and echocardiographic left ventricular mass index were measured at baseline and after 6 months of therapy in both groups.
  
  
  RESULTS
  More patients with hypertensive target organ damage were identified in the echo group as compared to the control group (58 of 91 [64%] v 42 of 86 [49%] patients (difference 15%, 95% CI 1%-29%). In the echo group, 41 patients (45%) received angiotensin II receptor antagonist therapy as compared to 27 patients (31%) in the control group (difference 14%, 95% CI 0-28%). After 6 months, there were no differences in mean left ventricular mass index, mean diastolic 24-h ambulatory BP monitoring, or mean systolic and diastolic office BP between the two groups.
  
  
  CONCLUSIONS
  In patients with newly detected hypertension, baseline echocardiography detects more patients with hypertensive target organ damage, but does not lead to a reduction in left ventricular mass index or improved BP control after 6 months of therapy.
authors.affiliation: Medical Outpatient Department, and Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland. bmartina@uhbs.ch
authors.forename: Benedict
authors.initials: B
authors.lastname: Martina
authors.forename: Alain
authors.initials: A
authors.lastname: Nordmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Dieterle
authors.forename: Joerg P
authors.initials: JP
authors.lastname: Sigle
authors.forename: Gunnar
authors.initials: G
authors.lastname: Bengel
authors.forename: Gerrit
authors.initials: G
authors.lastname: Kiefer
authors.forename: Edouard
authors.initials: E
authors.lastname: Battegay
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D019983:Guideline Adherence; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011320:Primary Health Care / Q000592:standards; D011446:Prospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers